ClinicalTrials.gg
RecruitingNCT06797635Updated Nov 12, 2026

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

A Phase 2 interventional study of Patritumab deruxtecan and Pembrolizumab in Breast Neoplasms and Breast Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 12, 2026Study completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing patritumab deruxtecan in Breast Neoplasms — 7 open to participants now, 9 under way, 1 of them phase 3. patritumab deruxtecan · Breast Neoplasms.

Planned enrollment
3rd of 12
372 · median 167
Started
2025
with 2 others
Phase 2
6 of 12
3 open now
Registered
10th of 12
by date
Lead sponsor
3 of 12
Merck Sharp & Dohme LLC

Among the 12 studies testing patritumab deruxtecan in Breast Neoplasms, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 2, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 12 studies testing patritumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About patritumab deruxtecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing patritumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
03

Conditions studied

  • Breast Neoplasms
  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non- (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current .
  • Has corneal disease
  • Has (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, , or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active and infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

    In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m\^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

    Biological: Patritumab deruxtecan · Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

    In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m\^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for \~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation \[gBRCAm\] only), capecitabine 1000-1250 mg/m\^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m\^2 IV Q3W or Q2W for 4 doses.

    Biological: Patritumab deruxtecan · Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Doxorubicin hydrochloride · Drug: Epirubicin hydrochloride · Drug: Cyclophosphamide · Drug: Capecitabine · Drug: Olaparib

  • Experimental
    Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

    In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m\^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for \~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m\^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m\^2 IV infusion Q3W or Q2W for 4 doses.

    Biological: Patritumab deruxtecan · Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Doxorubicin hydrochloride · Drug: Epirubicin hydrochloride · Drug: Cyclophosphamide · Drug: Capecitabine · Drug: Olaparib

  • Active comparator
    Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

    In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m\^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m\^2 (or epirubicin 90 mg/m\^2) IV infusion Q3W and cyclophosphamide 600 mg/m\^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m\^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Doxorubicin hydrochloride · Drug: Epirubicin hydrochloride · Drug: Cyclophosphamide · Drug: Capecitabine · Drug: Olaparib

Interventions

  • Administered via IV infusion as neoadjuvant treatment

    Also known as: MK-1022, HER3-DXd, U3-1402

  • BiologicalPembrolizumab

    Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

    Also known as: MK-3475, KEYTRUDA®

  • Administered via IV infusion as neoadjuvant treatment

    Also known as: TAXOL®, ONXAL®

  • Administered via IV infusion as neoadjuvant treatment

    Also known as: PARAPLATIN®

  • Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

    Also known as: ADRIAMYCIN®

  • Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

    Also known as: ELLENCE®

  • Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

    Also known as: CYTOXAN®

  • Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

    Also known as: XELODA®

  • Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

    Also known as: LYNPARZA®

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants Experiencing an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

    Time frame: Up to ~43 weeks

  2. Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)

    A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (\>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

    Time frame: Up to 21 days

  3. Part 1: Number of Participants who Discontinued Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

    Time frame: Up to ~30 weeks

  4. Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0

    pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

    Time frame: Up to ~30 weeks

  5. Part 2: Number of Participants Experiencing an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

    Time frame: Up to ~103 weeks

  6. Part 2: Number of Participants who Discontinued Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

    Time frame: Up to ~90 weeks

Secondary outcomes

  1. Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0

    pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

    Time frame: Up to ~30 weeks

  2. Part 2: Event-Free Survival (EFS)

    EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

    Time frame: Up to ~100 months

  3. Part 2: Overall Survival (OS)

    OS is defined as the time from randomization to date of death due to any cause.

    Time frame: Up to ~100 months

  4. Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)

    DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

    Time frame: Up to ~100 months

  5. Part 2: Residual Cancer Burden (RCB)

    RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0\< RCB score \<1.36), RCB-2 (1.36 \<RCB score \<3.28), and RCB-3 (RCB score \>3.28).

    Time frame: Up to ~30 weeks

07

Study locations

17 of 17 sites recruiting
  • UCLA Hematology/Oncology - Parkside ( Site 0021)
    Santa Monica, California 90404, United States
    Recruiting
    • Study Coordinator · Contact424-402-9520
  • Orchard Healthcare Research Inc. ( Site 0006)
    Skokie, Illinois 60077, United States
    Recruiting
    • Study Coordinator · Contact847-568-9932
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
    Billings, Montana 59102, United States
    Recruiting
    • Study Coordinator · Contact406-238-6685
  • Northwest Cancer Specialists, P.C. ( Site 8003)
    Happy Valley, Oregon 97015, United States
    Recruiting
    • Study Coordinator · Contact360-944-9889
  • SCRI Oncology Partners ( Site 7000)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Study Coordinator · Contact844-482-4812
  • Texas Oncology - DFW ( Site 8000)
    Dallas, Texas 75246, United States
    Recruiting
    • Study Coordinator · Contact214-370-1067
  • Houston Methodist Hospital ( Site 0022)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-441-9948
  • Virginia Oncology Associates (VOA) ( Site 8001)
    Norfolk, Virginia 23502, United States
    Recruiting
    • Study Coordinator · Contact844-482-4812
  • Seoul National University Hospital ( Site 2400)
    Seoul, 03080, South Korea
    Recruiting
    • Study Coordinator · Contact+82220720850
  • Severance Hospital, Yonsei University Health System ( Site 2402)
    Seoul, 03722, South Korea
    Recruiting
    • Study Coordinator · Contact+82222288135
  • Asan Medical Center ( Site 2401)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230103217
  • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
    Badalona, Catalonia 08916, Spain
    Recruiting
    • Study Coordinator · Contact+34934978925
  • Clinica Universidad de Navarra ( Site 1703)
    Madrid, Madrid, Comunidad de 28027, Spain
    Recruiting
    • Study Coordinator · Contact+34913531920
  • Hospital Universitario Reina Sofia ( Site 1702)
    Córdoba, 14004, Spain
    Recruiting
    • Study Coordinator · Contact+34 957012408
  • Taichung Veterans General Hospital ( Site 2502)
    Taichung, 407, Taiwan
    Recruiting
    • Study Coordinator · Contact+886423592525
  • National Cheng Kung University Hospital ( Site 2503)
    Tainan, 704, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535
  • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
    Taipei, 112, Taiwan
    Recruiting
    • Study Coordinator · Contact886228970011x1686
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 57 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 57 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2034 → Mar 2031, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 28, 2025
StartActual
Mar 20, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Mar 16, 2031was Dec 2034
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Northwest Cancer Specialists, P.C. ( Site 8003) · Happy Valley, United States
Show 1 removed
  • Northwest Cancer Specialists (Compass Oncology) ( Site 8003) · Tigard, United States
Nov 12, 2026
Study completion
Dec 31, 2034→Mar 16, 2031
Nov 6, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Northwest Cancer Specialists, P.C. ( Site 8003) · Happy Valley, United States
    Show 1 removed
    • Northwest Cancer Specialists (Compass Oncology) ( Site 8003) · Tigard, United States
  2. Nov 6, 2026
    Study completion Dec 31, 2034→Mar 16, 2031
    + 3 other changes: verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06797635
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Mar 20, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Mar 16, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion